Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22,354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective elimination of undifferentiated human pluripotent stem cells using pluripotent state-specific immunogenic antigen Glypican-3.
Okada M, Tada Y, Seki T, Tohyama S, Fujita J, Suzuki T, Shimomura M, Ofuji K, Kishino Y, Nakajima K, Tanosaki S, Someya S, Kanazawa H, Senju S, Nakatsura T, Fukuda K. Okada M, et al. Among authors: suzuki t. Biochem Biophys Res Commun. 2019 Apr 9;511(3):711-717. doi: 10.1016/j.bbrc.2019.02.094. Epub 2019 Mar 1. Biochem Biophys Res Commun. 2019. PMID: 30827508
Cancer immunotherapy-targeted glypican-3 or neoantigens.
Shimizu Y, Suzuki T, Yoshikawa T, Tsuchiya N, Sawada Y, Endo I, Nakatsura T. Shimizu Y, et al. Among authors: suzuki t. Cancer Sci. 2018 Mar;109(3):531-541. doi: 10.1111/cas.13485. Epub 2018 Feb 14. Cancer Sci. 2018. PMID: 29285841 Free PMC article. Review.
Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification.
Takahashi D, Kojima M, Suzuki T, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Ikeda M, Nakatsura T, Ochiai A, Nagino M. Takahashi D, et al. Among authors: suzuki t. Sci Rep. 2018 Sep 3;8(1):13166. doi: 10.1038/s41598-018-31383-9. Sci Rep. 2018. PMID: 30177687 Free PMC article.
Next-Generation Cancer Immunotherapy Targeting Glypican-3.
Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T. Shimizu Y, et al. Among authors: suzuki t. Front Oncol. 2019 Apr 10;9:248. doi: 10.3389/fonc.2019.00248. eCollection 2019. Front Oncol. 2019. PMID: 31024850 Free PMC article. Review.
First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors.
Shitara K, Ueha S, Shichino S, Aoki H, Ogiwara H, Nakatsura T, Suzuki T, Shimomura M, Yoshikawa T, Shoda K, Kitano S, Yamashita M, Nakayama T, Sato A, Kuroda S, Wakabayashi M, Nomura S, Yokochi S, Ito S, Matsushima K, Doi T. Shitara K, et al. Among authors: suzuki t. J Immunother Cancer. 2019 Jul 24;7(1):195. doi: 10.1186/s40425-019-0677-y. J Immunother Cancer. 2019. PMID: 31340866 Free PMC article. Clinical Trial.
Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma.
Shimizu Y, Mizuno S, Fujinami N, Suzuki T, Saito K, Konishi M, Takahashi S, Gotohda N, Tada T, Toyoda H, Kumada T, Miura M, Suto K, Yamaji T, Matsuda T, Endo I, Nakatsura T. Shimizu Y, et al. Among authors: suzuki t. Cancer Sci. 2020 Feb;111(2):334-342. doi: 10.1111/cas.14251. Epub 2019 Dec 28. Cancer Sci. 2020. PMID: 31774932 Free PMC article.
22,354 results
You have reached the last available page of results. Please see the User Guide for more information.